# Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

> **NCT05754736** · PHASE2 · UNKNOWN · sponsor: **The Second Affiliated Hospital of Shandong First Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Ametinib combined with bevacizumab

## Key facts

- **NCT ID:** NCT05754736
- **Lead sponsor:** The Second Affiliated Hospital of Shandong First Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05754736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05754736, "Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05754736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*